194 related articles for article (PubMed ID: 26853281)
1. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
2. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
Nazha A; Kantarjian H; Cortes J; Quintás-Cardama A
Expert Opin Pharmacother; 2013 Oct; 14(14):1977-86. PubMed ID: 23875628
[TBL] [Abstract][Full Text] [Related]
3. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Narayanan V; Gutman JA; Pollyea DA; Jimeno A
Drugs Today (Barc); 2013 Jul; 49(7):447-56. PubMed ID: 23914353
[TBL] [Abstract][Full Text] [Related]
4. Omacetaxine mepesuccinate for the treatment of leukemia.
Kim TD; Frick M; le Coutre P
Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
[TBL] [Abstract][Full Text] [Related]
5. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
[TBL] [Abstract][Full Text] [Related]
7. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
Chung C
Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
[TBL] [Abstract][Full Text] [Related]
8. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Damlaj M; Lipton JH; Assouline SE
Expert Opin Drug Saf; 2016 Sep; 15(9):1279-86. PubMed ID: 27367461
[TBL] [Abstract][Full Text] [Related]
9. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
Khoury HJ; Cortes J; Baccarani M; Wetzler M; Masszi T; Digumarti R; Craig A; Benichou AC; Akard L
Leuk Lymphoma; 2015 Jan; 56(1):120-7. PubMed ID: 24650054
[TBL] [Abstract][Full Text] [Related]
10. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
Alvandi F; Kwitkowski VE; Ko CW; Rothmann MD; Ricci S; Saber H; Ghosh D; Brown J; Pfeiler E; Chikhale E; Grillo J; Bullock J; Kane R; Kaminskas E; Farrell AT; Pazdur R
Oncologist; 2014 Jan; 19(1):94-9. PubMed ID: 24309980
[TBL] [Abstract][Full Text] [Related]
11. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
Akard L; Kantarjian HM; Nicolini FE; Wetzler M; Lipton JH; Baccarani M; Jean Khoury H; Kurtin S; Li E; Munteanu M; Cortes J
Leuk Lymphoma; 2016; 57(3):654-65. PubMed ID: 26436949
[TBL] [Abstract][Full Text] [Related]
12. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Nicolini FE; Khoury HJ; Akard L; Rea D; Kantarjian H; Baccarani M; Leonoudakis J; Craig A; Benichou AC; Cortes J
Haematologica; 2013 Jul; 98(7):e78-9. PubMed ID: 23753022
[No Abstract] [Full Text] [Related]
13. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cortes JE; Kantarjian HM; Rea D; Wetzler M; Lipton JH; Akard L; Khoury HJ; Michallet M; Guerci-Bresler A; Chuah C; Hellmann A; Digumarti R; Parikh PM; Legros L; Warzocha K; Baccarani M; Li E; Munteanu M; Nicolini FE
Cancer; 2015 May; 121(10):1637-44. PubMed ID: 25586015
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Cortes J; Digumarti R; Parikh PM; Wetzler M; Lipton JH; Hochhaus A; Craig AR; Benichou AC; Nicolini FE; Kantarjian HM;
Am J Hematol; 2013 May; 88(5):350-4. PubMed ID: 23468307
[TBL] [Abstract][Full Text] [Related]
15. Omacetaxine as an anticancer therapeutic: what is old is new again.
Wetzler M; Segal D
Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
[TBL] [Abstract][Full Text] [Related]
16. Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?
Visani G; Isidori A
Expert Opin Pharmacother; 2014 Jan; 15(1):1-3. PubMed ID: 24152096
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
Quintás-Cardama A; Kantarjian H; Cortes J
Cancer; 2009 Dec; 115(23):5382-93. PubMed ID: 19739234
[TBL] [Abstract][Full Text] [Related]
18. Omacetaxine mepesuccinate in chronic myeloid leukemia.
Al Ustwani O; Griffiths EA; Wang ES; Wetzler M
Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Cortes J; Lipton JH; Rea D; Digumarti R; Chuah C; Nanda N; Benichou AC; Craig AR; Michallet M; Nicolini FE; Kantarjian H;
Blood; 2012 Sep; 120(13):2573-80. PubMed ID: 22896000
[TBL] [Abstract][Full Text] [Related]
20. Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.
Kantarjian HM; O'Brien S; Cortes J
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):530-3. PubMed ID: 23790799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]